ArticleBMC infectious diseases2025
A new wave of resurgence for GII.4 Sydney in Huzhou, particularly GII.4 Sydney[P16], between 2019 and 2023.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Emergence of norovirus GII.7 and predominance of recombinant strains in pediatric acute gastroenteritis in Japan, 2021-2024.Archives of virology · 2026Article
- Increase of GII.17 Norovirus Infections During the 2024-2025 Season in Multiple Cities, China.Journal of medical virology · 2026Article
- Clinical, Molecular and Evolutionary Characterization of Noroviruses in Hospitalized Children With Acute Gastroenteritis in Vietnam, 2016 to 2021.Journal of medical virology · 2026Article
- Development and epidemiological investigation of a TaqMan-based multiplex real-time quantitative PCR assay for simultaneous detection of five bovine viruses (BVDV, AKAV, BNoV, BEV, and BCoV).Frontiers in veterinary science · 2026Article
- Increasing Predominance of Norovirus GII.17 over GII.4, United States, 2022-2025.Emerging infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNorovirus (NoV) infection is a major pathogen causing acute gastroenteritis (AGE) across all age groups worldwide. In the past few years, there were some situations where non-GII.4 genotypes of NoV became predominant in Huzhou region. To understand the latest prevalence of genotypes, we investigated the prevalence and genetic diversity of NoV in sporadic AGE cases from January 2019 to October 2023 in Huzhou City, Zhejiang, China.
methodsBetween January 2019 and October 2023, a total of 2846 specimens collected from patients with AGE were tested for NoV in Huzhou. Partial sequences of the RNA-dependent RNA polymerase (RdRp) and capsid gene of the positive samples were amplified by RT-PCR and sequenced. Genotyping of NoV sequences was carried out by the RIVM online NoV Genotyping Tool. Phylogenetic analyses were conducted using MEGA.
resultsIn total, 460 (16.16%) specimens were identified as NoV-positive. GII genogroup accounted for most of the NoV-positive specimens (83.70%, 385/460), followed by the GI genogroup (13.26%, 61/460), and dual infection with both GI and GII genogroups (3.04%, 14/460). NoV infection was found in all age groups tested. During this period, at least 20 NoV genotypes were observed, with GII.4 Sydney being the most predominant. Phylogenetic analysis of selected strains revealed that all GII.4 Sydney[P16] strains clustered together and were closely related to strains from Beijing, Shanghai, Hangzhou, Nanjing and the United States, with nucleotide homologies ranging from 96.9 to 99.7%.
conclusionsWe report that during the period from January 2019 to October 2023, the GII.4 Sydney is undergoing a new wave of resurgence, and becoming the main epidemic strain again, particularly GII.4 Sydney[P16] with P16 polymerase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.